Nothing Special   »   [go: up one dir, main page]

AR072593A1 - DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH - Google Patents

DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH

Info

Publication number
AR072593A1
AR072593A1 ARP090102787A ARP090102787A AR072593A1 AR 072593 A1 AR072593 A1 AR 072593A1 AR P090102787 A ARP090102787 A AR P090102787A AR P090102787 A ARP090102787 A AR P090102787A AR 072593 A1 AR072593 A1 AR 072593A1
Authority
AR
Argentina
Prior art keywords
pyridinyl
group
cycloalkyl
quinolinyl
alkylene
Prior art date
Application number
ARP090102787A
Other languages
English (en)
Inventor
Antoine Ravet
Jochen Goerlitzer
Ahmed Abouabdellah
Peter Hamley
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072593A1 publication Critical patent/AR072593A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)

Abstract

Reivindicacion 1: Compuesto que responde a la formula (1) en la que R2 representa un átomo de hidrogeno, de fluor o un grupo hidroxilo, ciano, trifluorometilo, alquilo C1-6, alcoxi C1-6, NR8R9; n representa un numero entero igual a 1, 2 o 3 y m representa un numero entero igual a 1 o 2; A representa un enlace covalente o un grupo alquileno C1-8; R1 representa un grupo R5 sustituido opcionalmente con uno o varios grupos R6 y/o R7; R5 representa un grupo elegido entre un fenilo, piridinilo, piridacinilo, pirimidinilo, piracinilo, triacinilo, naftalenilo, quinolinilo, isoquinolinilo, ftalacinilo, quinazolinilo, quinoxalinilo, cinolinilo, naftiridinilo; R6 representa un átomo de halogeno, un grupo ciano, -CH2CN, nitro, hidroxilo, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquileno C1-3, cicloalquilo C3-7-alquileno C1-3-O, NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9 o -O-(alquileno C1-3)-O-; R7 representa un grupo elegido entre un furanilo, pirrolilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, imidazolilo, pirazolilo, oxadiazol, tiadiazol, fenilo, piridinilo, piridacinilo, pirimidinilo, piracinilo, triazina, naftalenilo, quinolinilo, isoquinolinilo, ftalacinilo, quinazolinilo, quinoxalinilo, cinolinilo, naftiridini!o, imidazopirimidinilo, tienopirimidinilo, benzofuranilo, benzotienilo, bencimidazolilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, indolilo, isoindolilo, indazolilo, pirrolopiridinilo, furopiridinilo, tienopiridinilo, imidazopiridinilo, pirazolopiridinilo, oxazolopiridinilo, isoxazolopiridinilo, tiazolopiridinilo, feniloxi, benciloxi, pirimidinoxi; pudiendo estar el o los grupos R7 sustituidos con uno o varios grupos R6 idénticos o diferentes el uno del otro; R3 representa un átomo de hidrogeno, de fluor, un grupo alquilo C1-6 o un grupo trifluorometilo; R4 representa un tiazol sustituido opcionalmente con uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo alquilo C1-6, haloalquilo-C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquileno C1-3, haloalcoxi C1-6, ciano, -NR8R9, NR8COR9, NR8CO2R9, NR8SO2R9, NR8SO2NR8R9, COR8, CO2R8, CONR8R9, SO2R8, SO2NR8R9, -O-(alquileno C1-3)-O-, fenilo, feniloxi, benciloxi, piridinilo, piracinilo, piridacinilo, triacinilo o pirimidinilo; pudiendo estar los grupos fenilo, feniloxi, piridinilo, piracinilo, piridacinilo, triacinilo y pirimidinilo sustituidos con uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo ciano, nitro, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, haloalquilo C1-6, haloalcoxi C1-6, halotioalquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquileno C1-3; R8 y R9 representan independientemente el uno del otro un átomo de hidrogeno o un grupo alquilo C1-6-, o forman con el o los átomos a los que están unidos, en el caso de NR8R9, un ciclo elegido entre los ciclos azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, azepina, oxazepina o piperacina, estando este ciclo sustituido opcionalmente con un grupo alquilo C1-6 o bencilo; en el caso de NR8COR9, un ciclo lactama; en el caso de NR8CO2R9, un ciclo oxazolidinona, oxazinona u oxazepinona; en el caso de NR8SO2R9, un ciclo sultama; en el caso de NR8SO2NR8R9, un ciclo dioxido de tiazolidina o dioxido de tiadiazinano; en el estado de base o de sal de adicion a un ácido; estando excluidos los compuestos siguientes: 2-(3-{[2-(4-clorofenil)-4-metiltiazol-5-il]metoxicarbonilamino}piperidin-1-il)benzoato de metilo; ácido 2-3-{2-(4-clorofenil)-4-metiltiazol-5-il]metoxicarbonilamino}piperidin-1-il)benzoico; 3-(3-{[2-((4-clorofenil)-4-metiltiazol-5-il]metoxicarbonilamino}piperidin-1-il)benzoato de metilo; ácido 3-(3-{[2-(4-clorofenil)-4-metiltiazol-5-il]metoxicarbonilamino}piperidin-1-il)benzoico.
ARP090102787A 2008-07-23 2009-07-22 DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH AR072593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804179A FR2934265B1 (fr) 2008-07-23 2008-07-23 Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR072593A1 true AR072593A1 (es) 2010-09-08

Family

ID=40289184

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102787A AR072593A1 (es) 2008-07-23 2009-07-22 DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH

Country Status (28)

Country Link
US (1) US8912218B2 (es)
EP (1) EP2344486B1 (es)
JP (1) JP5452594B2 (es)
KR (1) KR20110034020A (es)
CN (1) CN102164920B (es)
AR (1) AR072593A1 (es)
AU (1) AU2009274355B2 (es)
BR (1) BRPI0916385A2 (es)
CA (1) CA2731789C (es)
CL (1) CL2011000147A1 (es)
CO (1) CO6351789A2 (es)
CY (1) CY1114519T1 (es)
DK (1) DK2344486T3 (es)
EA (1) EA018995B1 (es)
ES (1) ES2413304T3 (es)
FR (1) FR2934265B1 (es)
HR (1) HRP20130585T1 (es)
IL (1) IL210747A0 (es)
MA (1) MA32579B1 (es)
MX (1) MX2011000882A (es)
PE (1) PE20110384A1 (es)
PL (1) PL2344486T3 (es)
PT (1) PT2344486E (es)
SI (1) SI2344486T1 (es)
SM (1) SMT201300080B (es)
TW (1) TW201008937A (es)
UY (1) UY32004A (es)
WO (1) WO2010010288A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
FR2941696B1 (fr) * 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
AR082974A1 (es) 2010-09-15 2013-01-23 Hoffmann La Roche Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
DE102012018115A1 (de) 2012-09-13 2014-03-13 Matthias Lehr Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase
DE102013016573A1 (de) 2013-10-04 2015-04-09 Matthias Lehr 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854633B1 (fr) * 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
GB0417801D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
BRPI0515015A (pt) * 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Raf激酶抑制劑之化合物
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
UY32004A (es) 2010-02-26
CN102164920A (zh) 2011-08-24
EP2344486B1 (fr) 2013-03-27
EA018995B1 (ru) 2013-12-30
US20110212963A1 (en) 2011-09-01
CA2731789A1 (fr) 2010-01-28
CO6351789A2 (es) 2011-12-20
AU2009274355B2 (en) 2014-01-30
HRP20130585T1 (en) 2013-07-31
JP2011528704A (ja) 2011-11-24
WO2010010288A3 (fr) 2010-03-18
CN102164920B (zh) 2013-12-25
FR2934265B1 (fr) 2010-07-30
CA2731789C (fr) 2016-08-30
BRPI0916385A2 (pt) 2018-06-05
MX2011000882A (es) 2011-03-01
KR20110034020A (ko) 2011-04-04
SI2344486T1 (sl) 2013-07-31
JP5452594B2 (ja) 2014-03-26
PT2344486E (pt) 2013-06-27
PL2344486T3 (pl) 2013-08-30
SMT201300080B (it) 2013-09-06
PE20110384A1 (es) 2011-07-01
AU2009274355A1 (en) 2010-01-28
MA32579B1 (fr) 2011-08-01
EA201170237A1 (ru) 2011-10-31
EP2344486A2 (fr) 2011-07-20
CL2011000147A1 (es) 2011-06-17
WO2010010288A2 (fr) 2010-01-28
IL210747A0 (en) 2011-03-31
DK2344486T3 (da) 2013-07-08
US8912218B2 (en) 2014-12-16
ES2413304T3 (es) 2013-07-16
CY1114519T1 (el) 2016-10-05
FR2934265A1 (fr) 2010-01-29
TW201008937A (en) 2010-03-01

Similar Documents

Publication Publication Date Title
AR072593A1 (es) DERIVADOS DE ALQUILTIAZOLES, SU PREPARACIoN, COMPOSICIONES FARMACEUTICA QUE LOS CONTIENEN Y SU USO COMO INHIBIDORES DE LA ENZIMA FAAH
AR075247A1 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica
AR076562A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
AR076563A1 (es) Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica
AR074119A1 (es) Derivados de carbamatos de alquil-heterociclos, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en el tratamiento de enfermedades neurologicas,infecciosas y gastrointestinales, entre otras.
AR076561A1 (es) Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
AR044178A1 (es) Derivados de piperidinil- y piperazinil-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR054882A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
NI200800036A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR086881A1 (es) Derivados de picolinamida como agonistas del receptor cb2
PE20110303A1 (es) Derivados de heteroaril acetamidas como activadores de glucoquinasa
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas
PE20090150A1 (es) Compuestos derivados de oxadiazol
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20090595A1 (es) Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
AR053171A1 (es) N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR046625A1 (es) Derivados de pirazol y composiciones farmaceuticas.
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
PE20061316A1 (es) Derivados de pirazol como antagonistas del receptor de progesterona
ATE397446T1 (de) 4-phenylpiperidin-derivate als modulatoren der dopamin-neurotransmission
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal